Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 7/20 | 0.69 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.66 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | PRNP | P04156 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7877725 | 0.97 | ADORA2A (0.72) | GSRADORA2AMEN1KMT2ATDP1 | |
| Trifluoroacetic Acid SCHEMBL7960593 | 0.93 | ADORA2A (0.67) | GSRADORA2AMEN1KMT2ATDP1 | |
| Trifluoroacetic Acid SCHEMBL7875800 | 0.93 | GSR (0.72) | GSRADORA2AMEN1KMT2ATDP1 | |
| Trifluoroacetic Acid SCHEMBL7967139 | 0.92 | ADORA2A (0.66) | GSRADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL7880398 | 0.90 | MEN1 (0.79) | GSRADORA2AMEN1KMT2ATDP1 | |
| Trifluoroacetic Acid SCHEMBL30227435 | 0.90 | ADORA2A (0.63) | GSRADORA2AMEN1KMT2ATDP1 | |
| Trifluoroacetic Acid SCHEMBL7956392 | 0.90 | ADORA2A (0.63) | GSRADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL7869225 | 0.88 | MBNL1 (0.81) | GSRADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL18163841 | 0.87 | ADORA2A (0.80) | GSRADORA2AMEN1KMT2ATDP1 | |
| SCHEMBL20087077 | 0.87 | MBNL1 (0.80) | GSRADORA2AMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222069-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | INCELLDX, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20010031763-A1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | SMITHKLINE BEECHAM CORPORATION | 2001-10-18 | — | — | US | disclosed |
| US-6242459-B1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | SMITHKLINE BEECHAM CORPORATION | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031763-A1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | CCR5, CCR2, CCR1 | GSR 2496/4885ADORA2A 116/4885MEN1 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.